The Atellica IM High-Sensitivity Troponin I assay aids in rapid AMI detection and now integrates cTn values as a prognostic indicator to help predict risk of cardiac events and death for up to one year in symptomatic patients. This innovative prognostic claim supports more informed clinical decisions and has the potential to both reduce healthcare burden from repeated emergency visits and help prevent adverse cardiac outcomes.

At ADLM (booth #331), Tosoh will host a full line-up of industry experts to speak live on clinical diagnostic, educational and technology topics. For Immunoassay and HbA1c testing, Tosoh will showcase its next generation analyzers as well as proven solutions for fast, accurate and reliable results.